505 results on '"Cha, Eugene K."'
Search Results
2. Natural History and Genomic Landscape of Chemotherapy-Resistant Muscle-Invasive Bladder Cancer
3. Changes in the Perioperative Management and Outcomes of Patients With Upper Tract Urothelial Carcinoma Undergoing Radical Nephroureterectomy at Memorial Sloan Kettering Cancer Center: Over 20 Years of Experience
4. Long-term Outcomes of Local and Metastatic Small Cell Carcinoma of the Urinary Bladder and Genomic Analysis of Patients Treated With Neoadjuvant Chemotherapy
5. PD34-08 A PROSPECTIVE RANDOMIZED PHASE 3 TRIAL EVALUATING BENEFITS OF PERISTOMAL MESH PLACEMENT AT THE TIME OF RADICAL CYSTECTOMY AND ILEAL CONDUIT FORMATION
6. Prospective Phase II Study to Evaluate Response to Two Induction Courses (12 intravesical instillations) of BCG Therapy for High-risk Non–muscle-invasive Bladder Cancer
7. Association of patients’ sex with treatment outcomes after intravesical bacillus Calmette–Guérin immunotherapy for T1G3/HG bladder cancer
8. Response to 2 Induction Courses of Bacillus Calmette-Guèrin Therapy Among Patients With High-Risk Non–Muscle-Invasive Bladder Cancer
9. Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma
10. Clinical and Genomic Characterization of Bladder Carcinomas With Glandular Phenotype
11. The Impact of Plasmacytoid Variant Histology on the Survival of Patients with Urothelial Carcinoma of Bladder after Radical Cystectomy
12. Comparison of Postradical Cystectomy Ileus Rates Using GIA-80 Versus GIA-60 Intestinal Stapler Device
13. Correction: Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma
14. Clinical Outcomes of Patients With T1 Nested Variant of Urothelial Carcinoma Compared to Pure Urothelial Carcinoma of the Bladder
15. Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets
16. Neoadjuvant nivolumab (N) + ipilimumab (I) in cisplatin-ineligible patients with upper tract urothelial cancer (UTUC): Updated results.
17. Goal-directed versus Standard Fluid Therapy to Decrease Ileus after Open Radical Cystectomy: A Prospective Randomized Controlled Trial
18. Timing of blood transfusion and oncologic outcomes in patients treated with radical nephroureterectomy for upper tract urothelial carcinoma
19. Impact of Ureteroscopy Before Nephroureterectomy for Upper Tract Urothelial Carcinoma on Oncologic Outcomes
20. Genomic Biomarkers for the Prediction of Stage and Prognosis of Upper Tract Urothelial Carcinoma
21. Association of Biochemically Verified Post-Diagnosis Smoking and Nonmuscle-Invasive Bladder Cancer Recurrence Risk
22. Supplementary Methods from Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma
23. Table S1-S7 from Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis
24. Table S2 from Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma
25. Figure S1 from Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma
26. Figure S5 from Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis
27. Supplemental Data (Figures and Tables) from DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma
28. Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial Carcinoma
29. Neoadjuvant nivolumab (N) + ipilimumab (I) in cisplatin-ineligible patients with upper tract urothelial cancer (UTUC).
30. Chemotherapy and novel therapeutics before radical prostatectomy for high-risk clinically localized prostate cancer
31. Radical Transurethral Resection Alone, Robotic or Partial Cystectomy, or Extended Lymphadenectomy: Can We Select Patients with Muscle Invasion for Less or More Surgery?
32. Risk Factors for the Development of Parastomal Hernia after Radical Cystectomy
33. Association of Oncofetal Protein Expression with Clinical Outcomes in Patients with Urothelial Carcinoma of the Bladder
34. Low yield of surveillance imaging after surgery for T1 kidney cancer
35. Loss of SPINK1 expression is associated with unfavorable outcomes in urothelial carcinoma of the bladder after radical cystectomy
36. Impact of Histological Variants on Clinical Outcomes of Patients with Upper Urinary Tract Urothelial Carcinoma
37. Prognostic Value of Extranodal Extension and Other Lymph Node Parameters in Patients With Upper Tract Urothelial Carcinoma
38. Risk Stratification of Organ Confined Bladder Cancer After Radical Cystectomy Using Cell Cycle Related Biomarkers
39. Phase I study of intravesical anti-CD40 agonist antibody 2141-V11 for non-muscle invasive bladder cancer unresponsive to Bacillus Calmette-Guerin (BCG) therapy.
40. Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial
41. Feasibility of a geriatric comanagement (GERICO) pilot program for patients 75 and older undergoing radical cystectomy
42. Defining hereditary upper tract urothelial carcinoma: Implications for genetic testing and clinical management.
43. Neoadjuvant nivolumab (N) +/- ipilimumab (I) in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC).
44. Prognostic value of lymph node yield during nephroureterectomy for upper tract urothelial carcinoma
45. Genomic Biomarkers for the Prediction of Stage and Prognosis of Upper Tract Urothelial Carcinoma
46. EARLY OUTCOMES OF PROPHYLACTIC MESH PLACEMENT AT RADICAL CYSTECTOMY TO PREVENT PARASTOMAL HERNIAS: PD39-02
47. Role of extended lymphadenectomy
48. Prognostic Genetic Signatures in Upper Tract Urothelial Carcinoma
49. Rationale and Early Experience with Prophylactic Placement of Mesh to Prevent Parastomal Hernia Formation after Ileal Conduit Urinary Diversion and Cystectomy for Bladder Cancer
50. MP64-11 PROPHYLACTIC MESH PLACEMENT AT RADICAL CYSTECTOMY TO PREVENT PARASTOMAL HERNIAS: TECHNIQUE AND EARLY COMPLICATIONS
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.